# Tigermed

主要的中国 CRO 和咨询集团（如泰格医药 Tigermed）专门致力于弥合中国国家药品监督管理局 (NMPA) 和美国 FDA 之间的差距，以进行跨境药物开发。

Source: https://cn.bioecon.ru/companies/tigermed/
Updated: 2026-06-24

- 国家: China
- 代码: SZSE:300347

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 员工人数 | 截至2026年6月30日全球11,984名员工 | https://www.prnewswire.com/news-releases/tigermed-announces-2026-interim-results-302862700.html, https://www.tigermedgrp.com/en/our-company, https://www.tigermedgrp.com/files/2ac939093da780752dbc8ad73aa5fdd4.pdf |
| 营收 | 2026年上半年人民币37.076亿 | https://www.prnewswire.com/news-releases/tigermed-announces-2026-interim-results-302862700.html |
| 生产基地 | 截至2026年6月30日，在中国、美国和欧洲设有25个实验室设施，以及位于美国Exton的4,300平方米CDMO GMP生产设施 | https://tigermedgrp.com/files/2ac939093da780752dbc8ad73aa5fdd4.pdf, https://tigermedgrp.com/files/51167a318f1b3e1d5756e3f590d34911.pdf, https://www.prnewswire.com/news-releases/tigermed-announces-2026-interim-results-302862700.html, https://www.tigermedgrp.com/en/media-resources/press-releases/197, https://www.tigermedgrp.com/files/2ac939093da780752dbc8ad73aa5fdd4.pdf |
| 产能 | 截至2026年6月30日共建6个临床基地，研究床位共620张 | https://www.prnewswire.com/news-releases/tigermed-announces-2026-interim-results-302862700.html, https://www.tigermedgrp.com/en/media-resources/press-releases/197 |
| 认证 | Taya AI平台已取得ISO 20000与ISO 27001认证；实验室通过CAP认可 | https://tigermedgrp.com/files/51167a318f1b3e1d5756e3f590d34911.pdf, https://www.tigermedgrp.com/files/51167a318f1b3e1d5756e3f590d34911.pdf |
| 监管批准 | 2025年助力中国43项一类新药及5项创新医疗器械获批 | https://tigermedgrp.com/files/51167a318f1b3e1d5756e3f590d34911.pdf, https://www.tigermedgrp.com/files/2ac939093da780752dbc8ad73aa5fdd4.pdf, https://www.tigermedgrp.com/files/51167a318f1b3e1d5756e3f590d34911.pdf |
| 合作 | 2026年上半年与海正药业、英矽智能、三生制药及一家欧洲领先跨国制药公司签署战略合作协议 | https://www.prnewswire.com/news-releases/tigermed-announces-2026-interim-results-302862700.html |

独立来源: prnewswire.com

## 技术

- [CMC 监管咨询 (BLA/MAA)](https://cn.bioecon.ru/technology/cmc-regulatory-consulting/)
- [多司法辖区生物合规（FDA+EMA+NMPA+PMDA）](https://cn.bioecon.ru/technology/multi-jurisdictional-bio-compliance/)
- [指定患者计划与同情用药](https://cn.bioecon.ru/technology/named-patient-compassionate-use/)